Depression breakthrough? study tests if simple activity lifts energy
NCT ID NCT07059234
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study explores whether increasing non-exercise activity—like walking to the store or doing chores—can improve energy levels in people with major depression. Researchers will use smartphone prompts and activity trackers to encourage small movements throughout the day. The goal is to see if this personalized approach can reduce depressive symptoms and prevent relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- non-exercise activity encouragement via digital micro-interventions
- What this could lead to
- If successful, this could point toward a simple, personalized digital tool to help people with depression feel more energetic and reduce symptoms.
- What could go wrong
- This is an early-stage study with only 180 participants, so results may not apply to everyone. The intervention is behavioral and effects may be small or short-lived.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Bern
RECRUITINGBern, 3012, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a single dose of a new drug boost depression relief?
- Can a new pill ease depression without Add-Ons?
- Brain scans could make TMS for depression more precise
- Can brain training help depressed young adults stop ruminating?
- 45,000 students to be tracked: can we predict who will fall into depression?
- New depression pill BI 1569912 put to the test in 225-Person trial